相似文献
1
An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.
Rheumatology (Oxford). 2021 Feb 1;60(2):977-979. doi: 10.1093/rheumatology/keaa653.
2
Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
Clin Rheumatol. 2017 Jun;36(6):1395-1400. doi: 10.1007/s10067-017-3587-8. Epub 2017 Mar 2.
3
Switch from intravenous to subcutaneous abatacept: Our experience.
Reumatol Clin (Engl Ed). 2020 Mar-Apr;16(2 Pt 2):187-188. doi: 10.1016/j.reuma.2018.02.005. Epub 2018 Mar 9.
4
[Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].
Farm Hosp. 2014 Jul 1;38(4):257-65. doi: 10.7399/fh.2014.38.4.1137.
5
Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety.
J Rheumatol. 2015 Feb;42(2):193-5. doi: 10.3899/jrheum.141042. Epub 2014 Dec 15.
6
[Experience of monitoring subcutaneous biological treatment (adalimumab) by nurses in chronic inflammatory diseases].
Reumatol Clin. 2011 Sep-Oct;7(5):349-50. doi: 10.1016/j.reuma.2011.04.004. Epub 2011 Jun 30.
7
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
BMJ. 2019 Jan 24;364:l67. doi: 10.1136/bmj.l67.
8
Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis.
Clin Rheumatol. 2019 Aug;38(8):2109-2117. doi: 10.1007/s10067-019-04508-2. Epub 2019 Mar 26.
9
Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan.
Immunol Med. 2020 Sep;43(3):115-120. doi: 10.1080/25785826.2020.1757920. Epub 2020 May 12.
10
Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting.
Clin Ther. 2017 Aug;39(8):1600-1617. doi: 10.1016/j.clinthera.2017.06.007. Epub 2017 Jul 14.
引用本文的文献
1
Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice.
J Korean Med Sci. 2022 May 2;37(17):e138. doi: 10.3346/jkms.2022.37.e138.
2
Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series.
Clin Case Rep. 2022 Jan 20;10(1):e05205. doi: 10.1002/ccr3.5205. eCollection 2022 Jan.
3
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.
Adv Ther. 2022 Jun;39(6):2342-2364. doi: 10.1007/s12325-021-01990-6. Epub 2022 Jan 6.
4
Rheumatology and psychiatry: allies in times of COVID-19.
Clin Rheumatol. 2021 Aug;40(8):3363-3367. doi: 10.1007/s10067-021-05792-7. Epub 2021 May 28.
Zotero 插件